{"title":"抗eIF2B抗体阳性系统性硬化症患者的间质性肺病:病例报告和文献综述","authors":"Naoya Aoshiba , Kazutoshi Toriyama , Shohei Yamashita , Nao Shioiri , Yuko Iwata , Tomonori Uruma , Shinji Abe , Kenji Tsushima","doi":"10.1016/j.rmcr.2024.102141","DOIUrl":null,"url":null,"abstract":"<div><div>We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was diagnosed with interstitial lung disease associated with systemic sclerosis. Furthermore, systemic sclerosis was positive for the anti-eIF2B antibody. The presence of anti-eIF2B antibodies in systemic sclerosis is very rare, occurring in only 1–2.5 % of cases and seldom reported. Similar to our case, systemic sclerosis with positive anti-eIF2B antibodies has been reported to be more likely to be complicated by interstitial lung disease. Herein, we discuss our case in detail and summarize the previous findings.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"52 ","pages":"Article 102141"},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review\",\"authors\":\"Naoya Aoshiba , Kazutoshi Toriyama , Shohei Yamashita , Nao Shioiri , Yuko Iwata , Tomonori Uruma , Shinji Abe , Kenji Tsushima\",\"doi\":\"10.1016/j.rmcr.2024.102141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was diagnosed with interstitial lung disease associated with systemic sclerosis. Furthermore, systemic sclerosis was positive for the anti-eIF2B antibody. The presence of anti-eIF2B antibodies in systemic sclerosis is very rare, occurring in only 1–2.5 % of cases and seldom reported. Similar to our case, systemic sclerosis with positive anti-eIF2B antibodies has been reported to be more likely to be complicated by interstitial lung disease. Herein, we discuss our case in detail and summarize the previous findings.</div></div>\",\"PeriodicalId\":51565,\"journal\":{\"name\":\"Respiratory Medicine Case Reports\",\"volume\":\"52 \",\"pages\":\"Article 102141\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213007124001643\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007124001643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review
We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was diagnosed with interstitial lung disease associated with systemic sclerosis. Furthermore, systemic sclerosis was positive for the anti-eIF2B antibody. The presence of anti-eIF2B antibodies in systemic sclerosis is very rare, occurring in only 1–2.5 % of cases and seldom reported. Similar to our case, systemic sclerosis with positive anti-eIF2B antibodies has been reported to be more likely to be complicated by interstitial lung disease. Herein, we discuss our case in detail and summarize the previous findings.